(Total Views: 165)
Posted On: 10/09/2025 12:50:23 PM
Post# of 8722
Viant, VLMS & Electrome Pathway to $1 Billion+ Profit via BIEL
Step-by-Step Profit Trajectory
Accumulation Phase:
Viant/VLMS acquires 1 billion BIEL shares at ultra-low prices (e.g., $0.0002)
Total investment: $200,000 each
Electrome takes a 5% strategic equity stake in BIEL at the same ground-floor pricing
Investment: $200,000
Purpose: Accelerate therapeutic waveform discovery and AI-driven protocol optimization
Growth Catalysts:
BIEL hits key milestones:
U.S. distributor partnership
Insurance reimbursement
Retail adoption
Veterinary market penetration
FDA expansion
Electrome integration:
Electrome’s AI platform maps precision bioelectric signals
BIEL’s devices deliver those signals in wearable form
Joint R&D unlocks new indications (e.g., infection, inflammation, cancer)
Each milestone drives PPS upward, compounding Viant’s, VLMS and Electrome’s equity value
Profit Realization:
When BIEL PPS = $1 (after loans are paid off and share buyback is initiated):
Viant’s, VLMS and Electrome's 1B shares = $1 billion, ROI = 4,900x
Strategic Arbitrage Model
Fixed Cost Basis:
Viant/VLMS/Electrome locked in at $0.0002 securing asymmetric upside
Dynamic Equity Upside:
BIEL’s PPS climbs with each success
Viant, VLMS and Electrome’s balance sheets transform without additional capital outlay
Hybrid Operating-Investment Strategy:
Viant/VLMS supports BIEL’s growth operationally (manufacturing, modernization)
Electrome enhances therapeutic discovery and clinical targeting
All benefit from equity appreciation
Public Market Leverage
BIEL’s publicly traded shares act as a strategic asset:
Instant access to public markets
No IPO friction
Equity arbitrage without dilution
Balance Sheet Impact:
Revenue growth multiplied by PPS gains
Investor enthusiasm fuels sustained valuation
Tax-Efficient Wealth Creation
BIEL’s $40M tax-loss carryforwards shields early profits, enabling asymmetric upside with minimal tax exposure
Why BIEL + Electrome Is the Perfect Vehicle
Current PPS: $0.0001–$0.0002 (ground-floor entry)
FDA-cleared products: ActiPatch®, RecoveryRx®, RecoveryRx Vet®
Electrome’s platform: AI-driven waveform mapping, scalable bioelectric protocols
Market fit: Non-opioid, wearable, drug-free recovery
Veterinary vertical: Untapped goldmine with proven demand
Expanded indications: Infection, inflammation, cancer, pain—all within Electrome’s scope
Final Outcome: $1 Billion+ Profit
Viant/VLMS builds the infrastructure
Electrome enhances therapeutic precision and clinical reach
BIEL hits the milestones
PPS reaches $1 (after loans are paid off and a share buyback is initiated)
Electrome, VLMS and Viant’s $200k investment becomes $1 billion
All while benefiting from tax shields, public market leverage, and strategic control
Step-by-Step Profit Trajectory
Accumulation Phase:
Viant/VLMS acquires 1 billion BIEL shares at ultra-low prices (e.g., $0.0002)
Total investment: $200,000 each
Electrome takes a 5% strategic equity stake in BIEL at the same ground-floor pricing
Investment: $200,000
Purpose: Accelerate therapeutic waveform discovery and AI-driven protocol optimization
Growth Catalysts:
BIEL hits key milestones:
U.S. distributor partnership
Insurance reimbursement
Retail adoption
Veterinary market penetration
FDA expansion
Electrome integration:
Electrome’s AI platform maps precision bioelectric signals
BIEL’s devices deliver those signals in wearable form
Joint R&D unlocks new indications (e.g., infection, inflammation, cancer)
Each milestone drives PPS upward, compounding Viant’s, VLMS and Electrome’s equity value
Profit Realization:
When BIEL PPS = $1 (after loans are paid off and share buyback is initiated):
Viant’s, VLMS and Electrome's 1B shares = $1 billion, ROI = 4,900x
Strategic Arbitrage Model
Fixed Cost Basis:
Viant/VLMS/Electrome locked in at $0.0002 securing asymmetric upside
Dynamic Equity Upside:
BIEL’s PPS climbs with each success
Viant, VLMS and Electrome’s balance sheets transform without additional capital outlay
Hybrid Operating-Investment Strategy:
Viant/VLMS supports BIEL’s growth operationally (manufacturing, modernization)
Electrome enhances therapeutic discovery and clinical targeting
All benefit from equity appreciation
Public Market Leverage
BIEL’s publicly traded shares act as a strategic asset:
Instant access to public markets
No IPO friction
Equity arbitrage without dilution
Balance Sheet Impact:
Revenue growth multiplied by PPS gains
Investor enthusiasm fuels sustained valuation
Tax-Efficient Wealth Creation
BIEL’s $40M tax-loss carryforwards shields early profits, enabling asymmetric upside with minimal tax exposure
Why BIEL + Electrome Is the Perfect Vehicle
Current PPS: $0.0001–$0.0002 (ground-floor entry)
FDA-cleared products: ActiPatch®, RecoveryRx®, RecoveryRx Vet®
Electrome’s platform: AI-driven waveform mapping, scalable bioelectric protocols
Market fit: Non-opioid, wearable, drug-free recovery
Veterinary vertical: Untapped goldmine with proven demand
Expanded indications: Infection, inflammation, cancer, pain—all within Electrome’s scope
Final Outcome: $1 Billion+ Profit
Viant/VLMS builds the infrastructure
Electrome enhances therapeutic precision and clinical reach
BIEL hits the milestones
PPS reaches $1 (after loans are paid off and a share buyback is initiated)
Electrome, VLMS and Viant’s $200k investment becomes $1 billion
All while benefiting from tax shields, public market leverage, and strategic control
(1)
(0)
